Search Within

Joachim Yahalom

  1. "Hematologic Malignancies Research"
Formats
  1. Meeting Abstract (13)
  2. Journal Article (6)
  3. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (20)
  2. Department of Medicine (20)
  3. Hematologic Malignancies Research (20)
  4. Hematologic Malignancies, Division of (20)
  5. Radiation Oncology, Department of (20)
  6. Survivorship Research (20)

More Groups

People
  1. Maria Palomba (18)
  2. Ariela Noy (13)
  3. Gunjan Shah (12)
  4. Alison Moskowitz (11)
  5. Andrew Intlekofer (11)
  6. Andrew Zelenetz (11)

More People

Years
  1. 2025 (1)
  2. 2024 (1)
  3. 2023 (5)
  4. 2022 (1)
  5. 2021 (3)
  6. 2020 (3)

More Years

Publications
  1. Blood (10)
  2. Hematological Oncology (3)
  3. Journal of Clinical Oncology (2)
  4. Biology of Blood and Marrow Transplantation (1)
  5. Blood Advances (1)
  6. Blood Cancer Journal (1)

More Publications

Publishers
  1. American Society of Hematology (11)
  2. Wiley Blackwell (3)
  3. American Society of Clinical Oncology (2)
  4. Nature Publishing Group (2)
  5. Elsevier Inc. (1)
  6. John Wiley & Sons (1)

Results (20)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II trial of nivolumab plus doxorubicin, vinblastine, dacarbazine as frontline therapy in older adults with Hodgkin lymphoma
    Journal Article

    Torka, P.; Feldman, T.; Savage, K. J.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Capadona, C.; Subzwari, S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes
    Research Letter

    Lue, J. K.; Luttwak, E.; Rivas-Delgado, A.; Irawan, H.; Boardman, A.; Caron, P. C.; David, K.; Epstein-Peterson, Z.; Falchi, L.; Ghione, P.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • Impact of early histological transformation on survival in patients with follicular lymphoma
    Meeting Abstract

    Luttwak, E.; Qiu, A.; Okwali, M.; Rivas-Delgado, A.; Isgor, I.; Boardman, A. P.; Caron, P.; David, K. A.; Falchi, L.; Ghione, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Distinct patterns of CD4+and CD8+ T-cell clonal expansion enable broad clinical responses to pembrolizumab + GVD in patients with relapsed Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Rahman, J.; Ganesan, N.; Shah, G. L.; Noy, A.; Schoder, H.; Yahalom, J.; Kumar, A.; Falchi, L.; Hamlin, P. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Retrospective characterization of nodal marginal zone lymphoma
    Journal Article

    Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Dogan, A.; Epstein-Peterson, Z. D.; Falchi, L.; Hamlin, P. A.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma
    Meeting Abstract

    Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Five-year experience using bridging radiotherapy prior to chimeric antigen receptor (CAR) T-cell therapies for B-cell malignancies at Memorial Sloan Kettering Cancer Center
    Meeting Abstract

    Silverman, E. A.; Hubbeling, H.; Palomba, M. L.; Wijetunga, N. A.; Tringale, K.; Lebow, E.; Tomas, A. A.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Lesion characteristics and patterns of failure in diffuse large B cell lymphoma patients treated with bridging radiotherapy prior to chimeric antigen receptor T cell therapy
    Meeting Abstract

    Hubbeling, H.; Silverman, E. A.; Wijetunga, N. A.; Palomba, M. L.; Tringale, K.; Lebow, E.; Tomas, A. A.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; more...
    Blood (2021)

    Fulltext@MSK | Save